Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing.
BACKGROUND
Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment.


METHODS
In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies.


CONCLUSIONS
The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.
Department of Medical Informatics, School of Public Health, Jilin University, Changchun, 130021 China.
Liwei
L
Wang
Department of Health Science Research, Mayo Clinic, Rochester, MN 55901 USA.
Hongfang
H
Liu
Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD 21287 USA.
Christopher G
CG
Chute
Department of Information Systems, University of Maryland Baltimore County, Baltimore, MD 21055 USA.
Qian
Q
Zhu
Cancer; Drug repurposing; Network; Pharmacogenomics